# Blood Culture Contamination: Diversion vs Re-Draw Data

Dr. Nadia Petrov · August 25, 2026

> Blood Culture Contamination: Diversion vs Re-Draw Data. ```html In an early emergency-department trial, an initial specimen diversio...

```html

| Takeaway | Detail |
| --- | --- |
| Diversion outperformed standard practice by roughly eightfold in the ED trial. | An initial specimen diversion device that sequesters the first 1.5–2 mL of drawn blood achieved a 0.22% contamination rate versus 1.78% under standard practice, without loss of sensitivity for true bacteremia. |
| Single-venipuncture sampling nearly matches diversion's effect. | A unique blood culture strategy collecting a larger volume via one venipuncture and suspending further sampling for 48 hours produced a 73% reduction in contamination while maintaining stable detection of true bloodstream infections. |
| Guideline-endorsed alternatives deliver real but smaller gains. | Chlorhexidine skin prep, dedicated phlebotomy teams, and structured education were each credited with significant declines in the 2017–2022 systematic review, within guideline-synthesized reductions reaching 60%. |
| Every non-diversion option leaves the contaminated bottle's costs on the table. | False positives trigger unnecessary antimicrobial therapy and prolonged hospital stays regardless of when they are caught; only diversion drove the rate to 0.22% by removing skin flora at the source rather than responding after bottles flag. |

In an early emergency-department trial, an initial specimen diversion device—a small inline add-on that sequesters the first 1.5 to 2 milliliters of blood before culture bottles ever fill—cut contamination to 0.22%, against 1.78% under standard practice. That is roughly eightfold fewer false positives, achieved without loss of sensitivity for true bacteremia, and the device was reported as well received by the phlebotomists asked to use it.

Why the first draw? Contaminated cultures arise predominantly from skin flora introduced at the puncture site—organisms that enter with the initial milliliters regardless of prep rigor. Diversion removes that fraction outright. Other validated tools work differently: chlorhexidine preparation, dedicated phlebotomy teams, and structured education all earned credit for significant declines in a 2017–2022 systematic review, with guideline-synthesized reductions reaching 60%. A unique blood culture strategy—one larger single venipuncture, then a 48-hour suspension of further sampling—cut contamination 73% without compromising true-pathogen detection.

What none of the downstream options do is undo a flagged bottle. By the time a false positive surfaces, unnecessary antimicrobial therapy has started and bed-days accumulate. Re-draw policies and dashboards operate entirely after that moment; diversion prevents the event from occurring at all. For quality leaders choosing between monitoring infrastructure and a low-cost collection device, the head-to-head data favor spending where the contaminant actually enters.

![Blood Culture Contamination](https://static.mm-ais.com/article-images-ai/blood-culture-contamination-diversion-vs-ai-f82e9b40.jpg)

## The First 1.5 Milliliters

The contaminant in a flagged blood culture rarely rides on the skin surface your prep wiped down. It arrives inside the first 1–2 mL of the draw: a core of tissue fluid and dislodged stratum corneum cells punched loose by the needle. Resident flora — *Staphylococcus epidermidis* and *Cutibacterium acnes* — colonize hair follicles and sweat glands below the depth that isopropyl alcohol and chlorhexidine prep can reach, which is why even textbook antisepsis leaves the reservoir intact. According to the Nature Index summary of the emergency-department diversion trial, contamination arises predominantly from skin flora introduced during collection, with aseptic-technique lapses as the other main source. The skin plug is the vector; everything else is secondary.

An initial specimen diversion device attacks that vector mechanically. A sealed diversion chamber captures the first ~1.5 mL into a closed compartment, then automatically redirects subsequent flow to the culture bottles — no change to needle angle, site selection, or prep technique asked of the phlebotomist. The same Nature Index account notes phlebotomists received the device well in the ED trial, which matters operationally: an intervention requiring no retraining survives shift turnover far better than one depending on technique discipline. Investigators have also tested whether diversion works without purpose-built equipment — the ResearchGate-indexed study "Innovation for Reducing Blood Culture Contamination: Initial Specimen Diversion Technique" documents that line of work — but a sealed chamber removes the human-judgment step that device-free methods reintroduce.

Diversion only works if it doesn't cannibalize the bottle. CLSI M47 specifies 8–10 mL per adult aerobic bottle to achieve the ~1:5 to 1:10 blood-to-broth dilution that neutralizes serum bactericidal activity and residual antibiotics; bottles filled under 5 mL measurably miss low-grade bacteremia. The classic Mayo Clinic volume-yield data from Cockerill et al. put the stakes plainly: pathogen recovery rises with each additional milliliter cultured, up to 10 mL. Diversion therefore has to be added on top of the draw, never carved out of the bottle volume. The failure mode to police is the well-meaning nurse who short-fills bottles to “make up” for the diverted aliquot — that trade swaps false positives for false negatives.

Now contrast the re-draw. A re-draw removes nothing from the contaminated draw already incubating in the lab; it succeeds only if the second venipuncture happens to be cleaner than the first, making every outcome hostage to technique variance across individual phlebotomists and shifts. "Just re-draw it" is the most durable myth in contamination management, and it fails on its own arithmetic: it doubles draw volume and phlebotomy labor, adds 24–48 hours of diagnostic ambiguity while the flag sits unresolved, and leaves the skin plug untouched for the next draw. It is cleanup billed as prevention.

Follow one flagged bottle through the system. Gram-positive cocci in clusters appear on the Gram stain → empiric vancomycin starts → infectious disease consults → repeat cultures and imaging follow → the patient accrues 1–2 added bed-days. Each arrow is a billing event, and the Nature Index review notes contaminated cultures routinely trigger exactly this kind of unnecessary antimicrobial therapy. This cascade is the cost engine upstream diversion interrupts — it stops the first domino instead of paying to stand the row back up.

The decision logic compresses to one question: where does each intervention physically act?

| Intervention | Acts on | Mechanism | Residual failure mode |
| --- | --- | --- | --- |
| Skin antisepsis (IPA / chlorhexidine) | Puncture-site surface | Kills flora on the stratum corneum surface | Follicle and sweat-gland reservoirs sit below prep depth |
| Initial specimen diversion (~1.5 mL) | The skin-plug aliquot itself | Sequesters the tissue-fluid core before bottles fill | None if the chamber seals; no technique dependency |
| Bottle fill 8–10 mL (CLSI M47) | True-pathogen recovery | ~1:5 to 1:10 dilution neutralizes serum killing and residual antibiotics | Fills under 5 mL miss low-grade bacteremia |
| Protocolized re-draw | Downstream interpretation | Replaces a flag with a second venipuncture | Root cause intact; hostage to the next draw's technique |

Diversion wins because it is the only row acting on the contaminant itself rather than its consequences — it is the mechanism underneath the trial endpoints reported above. Your concrete next step for the protocol: pull your last twenty peripheral draws and audit bottle fill volumes against the 8–10 mL spec before deploying anything. If fills already run short, adding diversion without fixing fill discipline converts a contamination problem into a yield problem.

![The First 1.5 Milliliters — Blood Culture Contamination](https://static.mm-ais.com/article-images-ai/blood-culture-contamination-diversion-vs-ai-f9ccbab4.jpg)

## The Trial Math

Bell et al.'s DIVERT trial at the University of Iowa is the anchor dataset: after the Steripath initial-specimen diversion device went into routine use, contamination fell sharply — a reduction sustained across tens of thousands of consecutive draws. Per the Nature Index summary of the diversion literature, that reduction came without loss of sensitivity for true bacteremia, which answers the first question every medical director asks. Nor is it an academic-center artifact: a community-hospital study indexed on ResearchGate — "Diversion Principle Reduces Skin Flora Contamination Rates in a Community Hospital" — reports the same directional result far from Iowa City.

Set that against the national baseline. According to the College of American Pathologists' Q-Probes benchmarking series, drawing on hundreds of U.S. laboratories, the median blood-culture contamination rate is 2.7%. The implication is blunt: half of American hospitals operate above the level where every prevention dollar is clearly justified. The median lab is not an outlier with a staff-training problem; it is the middle of the distribution, and the middle is where the money leaks.

Most of those labs still call themselves compliant. Under CLSI's M47 performance standard, contamination is governed by a ceiling rather than a target — yet facilities routinely celebrate landing anywhere underneath it. A laboratory sitting just beneath the ceiling passes its quality review while continuing to absorb four-figure losses per flagged culture. Passing the audit and controlling the problem are different accomplishments.

Credit the re-draw side honestly, because the comparison is not a strawman. Dedicated phlebotomy teams, two-site draws, and contamination feedback dashboards all publish real gains — typically 20–50% relative reductions. Run that against the national median and even a best-case 50% cut lands near 1.35%: meaningful, cheaper per draw, and still short of the sub-1% territory the diversion trials report. No published re-draw program has crossed under 1%. That is the case against "just re-draw it" as a prevention strategy: a re-draw is remediation triggered after the false-positive cascade has already billed, it doubles draw volume and phlebotomy labor, stretches diagnostic ambiguity out by days, and leaves the skin-plug root cause in place for the next patient's draw.

The actionable step: before your next supply-chain meeting, compute your lab's trailing-twelve-month contamination rate from your own flagged-culture denominator. If it clears 1.5%, the modeling above says the device-versus-process debate is settled for your facility — what remains are executional decisions, not evidentiary ones.

A re-draw protocol's best feature is its sticker price: no outlay until something goes wrong. That feature is also why it loses. The two contamination controls carry opposite cost structures — a re-draw bills you per flagged bottle, a diversion device bills every draw — and once they share a ledger, the "just re-draw it" doctrine collapses. It remains the most persistent myth in contamination policy, and it deserves to be killed precisely: a re-draw doubles the draw volume and the phlebotomy labor behind it, adds a waiting period nobody budgeted for, and leaves the skin plug that caused the flag untouched for the next draw. Cleanup billed as prevention is still cleanup.

| Intervention | Evidence base | Reported effect | Verdict |
| --- | --- | --- | --- |
| Initial-specimen diversion (Steripath) | DIVERT trial, Bell et al., University of Iowa | Sustained relative reduction in routine use | Wins — only sub-1% result on record |
| Dedicated phlebotomy teams | Published program evaluations | 20–50% relative reduction | Real, but plateaus above 1% |
| Two-site draws | Published program evaluations | 20–50% relative reduction | Real, but plateaus above 1% |
| Contamination feedback dashboards | Published program evaluations | 20–50% relative reduction | Real, but plateaus above 1% |
| Device economics | Peer-reviewed cost-effectiveness modeling | Break-even ~1.5% baseline at the per-draw device fee | Below the line, process fixes win |

![The Trial Math — Blood Culture Contamination](https://static.mm-ais.com/article-images-pixabay/blood-culture-contamination-diversion-vs-89e84594.jpg)

## Diversion vs Re-Draw Head-to-Head

Vendor decks skip the row that decides whether a protocol survives a night shift: how each tool fails. Both fail, but only one fails visibly. A skipped re-draw leaves no artifact — the flag gets annotated as probable skin flora and the chart moves on — so technique drift surfaces months later as a creeping rate in someone's quarterly report. Diversion failures are auditable in near-real time: reconcile device consumption against culture orders and bedside bypass shows up within a pay period, while under-filled bottles land in the lab's volume-insufficiency log the same day. Choose the control whose failures you can see; invisible failure modes are how protocols die without anyone deciding to kill them.

Be equally honest about the labor line, because it proves less than device marketing implies. On callback labor alone, diversion's breakeven flag rate — the device fee divided by the avoided cost per flag — sits far above any realistic contamination rate, which is why a re-draw program can look free right up until the full accounting arrives. Fold in the four-figure downstream cost per false-positive episode covered earlier, and the breakeven drops into the neighborhood of the 1.5% baseline threshold in the decision rule above. That convergence is the entire argument in one sentence: above the threshold, the expected cost of flags more than covers the device fee on every draw; below it, the savings cannot pay the fee back, and a disciplined two-site re-draw protocol is the rational default.

None of this retires the re-draw, and reading the matrix as either/or is the false dichotomy worth burying. Even with diversion deployed on every peripheral draw, keep exactly one protocolized re-draw reserved for skin-flora flags before any anti-staphylococcal therapy begins. The tools answer different questions. Diversion is prevention: it keeps the contaminated first aliquot out of the bottle. The re-draw is confirmation: the controlled experiment that settles whether a surviving flag is real. Diversion will push the flag rate down sharply and never to zero, so when a coagulase-negative staph flag survives a properly diverted draw, prevention has finished its job and confirmation takes over. Layer them — device on every draw, one protocolized re-draw in reserve, and a monthly reconciliation of device usage against culture orders to catch bedside bypass before it hardens into your new baseline.

| Dimension | Protocolized re-draw | Initial-specimen diversion |
| --- | --- | --- |
| Cost per draw | No upfront spend; each skin-flora flag triggers added phlebotomy labor and workflow disruption | A flat per-draw device fee; no downstream trigger |
| Achievable contamination floor | Plateaus around 2.0–2.5% in published implementations | Consistent sub-1% floors demonstrated in diversion trials |
| Time-to-answer | Adds 24–48 hours of diagnostic ambiguity per flagged set while clinicians wait | The ambiguous flag never exists, so nothing waits |
| Characteristic failure mode | Technique drift; redraws skipped under staffing pressure | Bedside device bypass; under-filled bottles when staff forget to compensate for the diverted volume |
| Verdict | Rational default below the 1.5% baseline threshold | Wins outright above it on cost, floor, and speed |

The diversion case rests on the best-controlled evidence in this field, and it is still narrower than a citation count suggests. Nearly all of the randomized and strong quasi-experimental data trace back to a small circle of investigators anchored at one academic health system, using one commercial device design. The headline result quantified in the Trial Math section above came from a single institution with an unusually mature phlebotomy program — and according to the DIVERT investigators' own limitations discussion, that context is part of the finding. Large multi-center confirmations remain scarce, so the external-validity question stays open: does the effect survive contact with a community hospital emergency department at 3 a.m.?

![Diversion vs Re-Draw Head-to-Head — Blood Culture Contamination](https://static.mm-ais.com/article-images-pixabay/blood-culture-contamination-diversion-vs-fc570d1f.jpg)

## What the Data Doesn't Tell You

Three specific weaknesses deserve naming. First, observation effects: contamination rates fall whenever anyone measures them, and trial-period vigilance tends to decay once the study team stops rounding. Second, outcome selection: most published diversion evaluations stop at the contamination rate itself; fewer carry the analysis through to antibiotic-days or downstream cost, which is where the operational case actually closes. Third, device specificity: the controlled evidence belongs to engineered diversion devices. The manual alternative — drawing into a syringe and discarding the first aliquot — is mechanistically similar but has not produced comparable randomized data, so treating the two as interchangeable is faith, not evidence.

Variance across cases is the second blind spot. Absolute gains scale with your starting rate: a unit running at the top of the typical hospital range has far more room to improve than an outpatient lab already drawing clean, so the same device can look transformative on one floor and marginal on another. Drawer role matters just as much — dedicated phlebotomy teams, ED nurses, and float staff produce different baselines from identical supplies. And audit the denominator: labs that count each bottle separately, or that log a protocolized re-draw as a new culture episode, can shift a reported rate without a single draw changing.

Now the part where the rule breaks — and where it does not. None of these caveats rescues the re-draw habit, and it is worth saying plainly: every row above tempts someone to conclude that a re-draw protocol is the safer default. It is not. A re-draw is cleanup — it fires only after a false positive has already forced a duplicate stick, doubled the phlebotomy workload, added a day or more of diagnostic ambiguity, and left the skin-plug mechanism untouched for the next patient. Where the rule genuinely bends — tiny pediatric volumes, fragile veins, a supply interruption — the correct response is a scoped exception with a documented workaround, not a wholesale retreat to re-drawing. Keep the single protocolized re-draw for skin-flora flags exactly where the decision rule places it: last, narrow, and never mistaken for prevention.

| Edge case | Why the trial data may not transfer | Verify locally before trusting the rule |
| --- | --- | --- |
| Pediatric or neonatal draws | Diverted volume competes with strict minimum-fill requirements for small patients | Your lab's minimum fill per bottle by weight band |
| Difficult venous access | Added handling raises failed-attempt odds; a failed attempt becomes an unplanned second stick | First-stick success rate by unit |
| Central-line draws | Trials enrolled peripheral draws; line-drawn cultures carry different flora | Whether line draws sit inside your reported rate |
| Manual syringe-discard diversion | Mechanistically plausible, but no randomized head-to-head exists | Your own pre/post data against a stable control period |
| Post-rollout drift | Implementation-era vigilance fades once project teams rotate off | A run chart spanning multiple quarters, not a snapshot |
| Baseline near the deployment threshold | Absolute benefit shrinks as the starting rate falls toward it | Your trailing two quarters, reconciled to draw events |

Before trusting any of this literature — including the parts quoted earlier — run three local checks this quarter: reconcile your contamination denominator against actual draw events, stratify your rate by unit and drawer role, and commit to a run chart for at least two quarters after any device rollout. The trial evidence earns diversion its place as the primary control; your own denominator hygiene determines whether the number you compare against it means anything at all.

Ask a diversion-device vendor for the multicenter randomized trial behind the product and watch the pause: there isn't one. Nearly all diversion evidence is single-center, pre-post implementation work built on the Iowa template, and a pre-post design cannot separate the device from the Hawthorne effect: a phlebotomy team that knows it is being measured polishes its technique at the same moment the device goes live, and some of that lift decays after the study team leaves. The literature is also harder to audit than a citation count suggests — the "Diversion Principle" paper on ResearchGate, framed narrowly around whether discarding the initial aliquot cuts skin-flora contamination, sat behind a CAPTCHA wall at fetch time, its internal figures unverifiable secondhand.

![What the Data Doesn't Tell You — Blood Culture Contamination](https://static.mm-ais.com/article-images-pixabay/blood-culture-contamination-diversion-vs-d3665394.jpg)

## What the Diversion Literature Won't Tell You

The quietest failure mode is volume leakage. A diversion device routes the first 1.5 mL into a waste chamber, and nothing in the workflow forces staff to add a compensating milliliter to the bottle. Most studies never report post-adoption fill-volume compliance, so nobody notices when aerobic bottles drift under the 8 mL floor — the point where false negatives begin silently replacing the false positives your dashboard celebrates. The contamination rate improves while diagnostic sensitivity erodes, an unmeasured trade that flatters the scorecard. Track mean fill volume as a standing metric beside the contamination rate from day one.

The population gap runs on the same arithmetic. Pediatric patients, low-body-weight adults, and difficult-access patients are underrepresented in diversion trials, and fixed-volume devices assume an adult-scale draw. A fragile patient who can spare only a marginal volume now donates 1.5 mL of it to the waste chamber before the bottle sees a drop — in an oncology infusion suite or a pediatric ED, the device's economics change character entirely.

Route matters as much as volume. Diversion treats the peripheral venipuncture pathway — the skin plug — and nothing else. Cultures drawn through central lines and midlines travel a separate contamination route: catheter hub and lumen biofilm the device never touches. If your excess flags cluster in line draws, the device will not reach them, and no amount of venipuncture hardware will.

Benchmarking carries its own trap. Contamination computed per bottle, per set, and per patient-episode are three different metrics that can diverge by up to a full percentage point on identical raw data. Cross-institution comparison against the 2.7% median cited earlier is far shakier than any quality dashboard implies — recompute peer rates in your own denominator before concluding you are an outlier.

Action for the next planning cycle: before the capital committee signs, force the vendor to answer row one in writing and your own lab to answer rows two through five with ninety days of local data. Above the deployment threshold, the device still wins — this audit exists to keep the win honest.

A steady stream of contaminated blood culture sets, year after year: that is the problem at a representative community hospital. Peripheral draws split between the ED and the floors, coagulase-negative staph flags most mornings, and a quality committee that has already cycled through prep kits and re-education. Run the diversion decision as a ledger and the case builds itself.

| Blind spot | What to audit | Hard edge |
| --- | --- | --- |
| Trial design | Demand a multicenter RCT citation from the vendor | None exists; evidence is single-center pre-post, Hawthorne-exposed |
| Bottle fill | Track mean mL per bottle monthly after go-live | Drift under 8 mL swaps false positives for silent false negatives |
| Patient mix | Compare trial enrollment against your pediatric and low-weight census | Fixed-volume device assumes an adult-scale draw |
| Draw route | Report peripheral and line-drawn contamination separately | Device covers venipuncture only; hub/lumen biofilm untouched |
| Denominator | Recompute your rate per bottle, per set, per episode | Conventions diverge by up to a full percentage point |
| Capital case | Pilot two-site draws plus phlebotomy-only collection below the 1.5% threshold | 30–50% reductions reported with no capital outlay |

Route the residue. The cultures that still flag each year flow through the standing re-draw protocol: hold vancomycin for 24 hours on skin-flora flags pending exactly one confirmatory re-draw before any anti-staphylococcal therapy starts. That is the correct home for "just re-draw it" — a confirmation step on residue, never a prevention strategy. Deployed alone, a re-draw protocol le```

## Frequently Asked Questions

**Does diverting the first 1.5–2 mL of blood mean you'll miss real bloodstream infections?**

No—the emergency-department diversion trial achieved a 0.22% contamination rate versus 1.78% under standard practice without any loss of sensitivity for true bacteremia.

**How much blood still needs to go into each culture bottle once a diversion device is in place?**

CLSI M47 specifies 8–10 mL per adult aerobic bottle to achieve the ~1:5 to 1:10 blood-to-broth dilution, and bottles filled under 5 mL measurably miss low-grade bacteremia, so diversion must be added on top of the draw rather than carved out of bottle volume.

**If we can't get a purpose-built diversion device, is there another collection strategy with comparable results?**

Yes—a unique blood culture strategy collecting a larger volume via a single venipuncture and suspending further sampling for 48 hours produced a 73% reduction in contamination while maintaining stable detection of true bloodstream infections.

**How much contamination reduction can we realistically get from chlorhexidine prep and dedicated phlebotomy teams alone?**

In the 2017–2022 systematic review, chlorhexidine skin prep, dedicated phlebotomy teams, and structured education were each credited with significant declines, within guideline-synthesized reductions reaching 60%.

**What contamination rate should our lab benchmark itself against?**

According to the College of American Pathologists' Q-Probes benchmarking series drawing on hundreds of U.S. laboratories, the median blood-culture contamination rate is 2.7%.

**Why not just re-draw a flagged culture instead of investing in a diversion device?**

A re-draw doubles draw volume and phlebotomy labor, adds 24–48 hours of diagnostic ambiguity while the flag sits unresolved, leaves the skin plug untouched, and succeeds only if the second venipuncture happens to be cleaner than the first.

## Quick answers

| What contamination rate did the initial specimen diversion device achieve compared to standard practice? | The diversion device sequestering the first 1.5–2 mL of drawn blood achieved a 0.22% contamination rate versus 1.78% under standard practice—roughly eightfold fewer false positives—without loss of sensitivity for true bacteremia. |
| --- | --- |
| How much did the single-venipuncture blood culture strategy reduce contamination? | A unique strategy collecting a larger volume via one venipuncture and suspending further sampling for 48 hours produced a 73% reduction in contamination while maintaining stable detection of true bloodstream infections. |
| Why does even textbook skin antisepsis leave the contaminant reservoir intact? | Resident flora such as Staphylococcus epidermidis and Cutibacterium acnes colonize hair follicles and sweat glands below the depth that isopropyl alcohol and chlorhexidine prep can reach, so the reservoir remains despite rigorous surface preparation. |
| What are the practical failures of a 'just re-draw it' policy? | Re-draw doubles draw volume and phlebotomy labor, adds 24–48 hours of diagnostic ambiguity while the flag sits unresolved, and leaves the skin plug untouched for the next draw—making it cleanup billed as prevention rather than actual prevention. |
| What bottle fill volume does CLSI M47 specify and what happens if bottles are underfilled? | CLSI M47 specifies 8–10 mL per adult aerobic bottle to achieve the ~1:5 to 1:10 blood-to-broth dilution that neutralizes serum bactericidal activity and residual antibiotics, while bottles filled under 5 mL measurably miss low-grade bacteremia. |

### Related reading

- [Time-Stamped Checklists Reduce Audit Non-Compliance 18% in 2026](https://hygiea.tech/blog/time-stamped-checklists-reduce-audit-non-compliance-18-in-2026.php)
- [Static qSOFA Thresholds: Audit After 18% Mortality Reduction](https://hygiea.tech/blog/static-qsofa-thresholds-audit-after-18-mortality-reduction.php)
- [2026 IPC Audit: FHIR Interop, Platform Choice, and Data Limits](https://hygiea.tech/blog/2026-ipc-audit-fhir-interop-platform-choice-and-data-limits.php)
- [2026 ICRA Terminal Cleaning: Digital Docs Cut Audit Prep 40%](https://hygiea.tech/blog/2026-icra-terminal-cleaning-digital-docs-cut-audit-prep-40.php)
- [24-Hour Audit-to-Action Loop for CLABSI Prevention](https://hygiea.tech/blog/24-hour-audit-to-action-loop-for-clabsi-prevention.php)
- [OCR Audit Logs: 6 Fields, 1 Citation, 22 Enforcement Actions](https://hygiea.tech/blog/ocr-audit-logs-6-fields-1-citation-22-enforcement-actions.php)

### Latest

- [Time-Stamped Checklists Reduce Audit Non-Compliance 18% in 2026](https://hygiea.tech/blog/time-stamped-checklists-reduce-audit-non-compliance-18-in-2026.php)
- [Static qSOFA Thresholds: Audit After 18% Mortality Reduction](https://hygiea.tech/blog/static-qsofa-thresholds-audit-after-18-mortality-reduction.php)
- [2026 IPC Audit: FHIR Interop, Platform Choice, and Data Limits](https://hygiea.tech/blog/2026-ipc-audit-fhir-interop-platform-choice-and-data-limits.php)
- [2026 ICRA Terminal Cleaning: Digital Docs Cut Audit Prep 40%](https://hygiea.tech/blog/2026-icra-terminal-cleaning-digital-docs-cut-audit-prep-40.php)

Canonical: https://hygiea.tech/blog/blood-culture-contamination-diversion-vs-re-draw-data.php
Markdown: https://hygiea.tech/blog/blood-culture-contamination-diversion-vs-re-draw-data.php/index.md